Myogen Drops Heart Failure Agent Following Failed Phase III Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral PDE-3 inhibitor enoximone failed to show a significant benefit for any of three co-primary endpoints in two Phase III trials.
You may also be interested in...
GSK Partners With Myogen Ahead Of Ambrisentan Launch
GlaxoSmithKline will commercialize Myogen’s selective endothelin receptor antagonist for pulmonary arterial hypertension outside the U.S. following approval; Myogen will take over marketing of GSK’s Flolan in the U.S.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.